LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Buprenorphine: Far Beyond the "Ceiling".

    Infantino, Rosmara / Mattia, Consalvo / Locarini, Pamela / Pastore, Antonio Luigi / Maione, Sabatino / Luongo, Livio

    Biomolecules

    2021  Volume 11, Issue 6

    Abstract: Chronic pain, including neuropathic pain, represents an untreated disease with important repercussions on the quality of life and huge costs on the national health system. It is well known that opioids are the most powerful analgesic drugs, but they ... ...

    Abstract Chronic pain, including neuropathic pain, represents an untreated disease with important repercussions on the quality of life and huge costs on the national health system. It is well known that opioids are the most powerful analgesic drugs, but they represent the second or third line in neuropathic pain, that remain difficult to manage. Moreover, these drugs show several side effects that limit their use. In addition, opioids possess addictive properties that are associated with misuse and drug abuse. Among available opioids compounds, buprenorphine has been suggested advantageous for a series of clinical reasons, including the effectiveness in neuropathic pain. Some properties are partly explained by its unique pharmacological characteristics. However, questions on the dynamic profile remain to be answered. Pharmacokinetics optimization strategies, and additional potentialities, are still to be explored. In this paper, we attempt to conceptualize the potential undiscovered dynamic profile of buprenorphine.
    MeSH term(s) Analgesics/pharmacokinetics ; Analgesics/therapeutic use ; Buprenorphine/pharmacokinetics ; Buprenorphine/therapeutic use ; Chronic Pain/drug therapy ; Chronic Pain/metabolism ; Humans ; Neuralgia/drug therapy ; Neuralgia/metabolism ; Quality of Life
    Chemical Substances Analgesics ; Buprenorphine (40D3SCR4GZ)
    Language English
    Publishing date 2021-05-31
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2701262-1
    ISSN 2218-273X ; 2218-273X
    ISSN (online) 2218-273X
    ISSN 2218-273X
    DOI 10.3390/biom11060816
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Tapentadol prolonged release for managing moderate to severe chronic neck pain with or without a neuropathic component.

    Coluzzi, Flaminia / Pergolizzi, Joseph V / Giordan, Enrico / Locarini, Pamela / Boaro, Alessandro / Billeci, Domenico

    Current medical research and opinion

    2020  Volume 36, Issue 4, Page(s) 651–659

    Abstract: Background: ...

    Abstract Background:
    MeSH term(s) Adult ; Aged ; Chronic Pain/drug therapy ; Chronic Pain/psychology ; Delayed-Action Preparations ; Female ; Humans ; Male ; Middle Aged ; Neck Pain/drug therapy ; Neck Pain/psychology ; Neuralgia/drug therapy ; Neuralgia/psychology ; Quality of Life ; Retrospective Studies ; Tapentadol/administration & dosage
    Chemical Substances Delayed-Action Preparations ; Tapentadol (H8A007M585)
    Language English
    Publishing date 2020-02-06
    Publishing country England
    Document type Journal Article ; Observational Study
    ZDB-ID 80296-7
    ISSN 1473-4877 ; 0300-7995
    ISSN (online) 1473-4877
    ISSN 0300-7995
    DOI 10.1080/03007995.2020.1722083
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 955: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease.

    Coluzzi, Flaminia / Raffa, Robert B / Pergolizzi, Joseph / Rocco, Alessandra / Locarini, Pamela / Cenfra, Natalia / Cimino, Giuseppe / Mattia, Consalvo

    Journal of pain research

    2015  Volume 8, Page(s) 229–238

    Abstract: Context: Myeloma bone disease (MBD) is a devastating complication of multiple myeloma that leads to severe pain.: Objectives: The aim of this study was to evaluate the efficacy and tolerability of tapentadol prolonged release (PR) in the management ... ...

    Abstract Context: Myeloma bone disease (MBD) is a devastating complication of multiple myeloma that leads to severe pain.
    Objectives: The aim of this study was to evaluate the efficacy and tolerability of tapentadol prolonged release (PR) in the management of patients with MBD suffering from moderate-to-severe cancer pain.
    Methods: A 12-week prospective study was carried out in 25 opioid-naïve MBD patients. Patients initially received twice-daily doses of tapentadol PR 50 mg. Doses were then managed to maintain adequate relief or dose-limiting toxicity. The following parameters were recorded at weekly intervals for 4 weeks, and then at weeks 8 and 12: pain, opioid-related adverse effects, use of other analgesics, DN4 (Douleur Neuropathique 4) score. Quality of life (SF-36 [36-item short-form health survey]) was measured at baseline and at final evaluation.
    Results: Of 25 patients, 22 completed the study. Pain intensity significantly decreased from baseline to all the week intervals (P<0.01). Quality of life significantly improved with respect to all SF-36 subscale parameters (P<0.01), and so did both the physical and mental status (P<0.01). Tapentadol PR significantly reduced DN4 mean value (P<0.01) and the number of patients with neuropathic component (DN4 ≥4) (P<0.01). After 8 weeks of treatment, all patients were negative for the DN4 score. Tapentadol PR was well tolerated, and the use of other analgesics was reduced during the study period.
    Conclusion: Tapentadol PR started in doses of 100 mg/day was effective and well tolerated in opioid-naïve MBD patients with moderate-to-severe pain. Tapentadol PR can be considered a first-choice opioid in cancer patients suffering from mixed pain with a neuropathic component.
    Keywords covid19
    Language English
    Publishing date 2015-05-08
    Publishing country New Zealand
    Document type Journal Article
    ZDB-ID 2495284-9
    ISSN 1178-7090
    ISSN 1178-7090
    DOI 10.2147/JPR.S83490
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top